Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Summary

The purpose of this study is to demonstrate the clinical equivalence of formoterol-HFA pMDI 12µg/actuation administered twice daily to formoterol DPI 12µg/capsule delivered by the Aerolizer inhaler and administered twice daily in patients with COPD.

Timeline

Start

2005-08

Primary completion

2006-04

Completion

2006-10

Drugs

Indications